Gulley James L, Madan Ravi A, Heery Christopher R
From the Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e166.
Results of recent clinical trials have intensified interest in immunotherapy for cancer. Among the most promising candidates for immunotherapy are patients with prostate cancer. Results of therapeutic vaccine clinical trials in this population have suggested statistically significant and clinically meaningful improvements in overall survival, with substantially fewer side effects than with chemotherapy. Of particular interest are sipuleucel-T, the first U.S. Food and Drug Administration-approved therapeutic cancer vaccine, and PSA-TRICOM (PROSTVAC), a therapeutic cancer vaccine in phase III testing. The immune checkpoint inhibitor ipilimumab is also stirring considerable interest, with two phase III trials ongoing in prostate cancer. This article highlights data emerging from these trials and addresses remaining questions and practical clinical implications of this therapeutic strategy.
近期临床试验结果激发了对癌症免疫疗法的兴趣。前列腺癌患者是免疫疗法最有前景的候选对象之一。该人群治疗性疫苗临床试验结果表明，总体生存率有统计学意义且具有临床意义的改善，副作用比化疗少得多。特别值得关注的是美国食品药品监督管理局批准的首款治疗性癌症疫苗sipuleucel-T，以及正在进行III期试验的治疗性癌症疫苗PSA-TRICOM（PROSTVAC）。免疫检查点抑制剂伊匹单抗也引发了极大关注，目前有两项针对前列腺癌的III期试验正在进行。本文重点介绍了这些试验中出现的数据，并探讨了该治疗策略尚存的问题及实际临床意义。
